Rhonda Q. Freeman, Ph.D.
LICENSE:
FL #PY 6252
SPECIALTY:
Neuropsychologist
EDUCATION:
Drexel University
Bachelor of Science (Psychology)
Philadelphia, PA
June 1992
Drexel University
Master of Science (Neuropsychology)
Philadelphia, PA
November 1996
Drexel University
Doctor Of Philosophy (Clinical Psychology)
Emphasis in Neuropsychology
Philadelphia, PA
June 1999
POST DOCTORAL FELLOWSHIP:
University of Miami School of Medicine/
Mount Sinai Medical Center
Wien Center for Memory Disorders
and Alzheimer’s Disease
Miami Beach, FL 9/99 – 9/00
CLINICAL TRAINING:
Riddle Memorial Hospital-
Neurobehavioral Unit
Media, PA
9/98 – 9/99
INTERNSHIP:
Norristown State Hospital
Norristown, PA
Forensic Unit
9/97 – 9/98
Philadelphia Geriatric Center
Philadelphia, PA
9/97 – 9/98
PRACTICUM TRAINING:
Crozer-Chester Medical Center
Upland, PA
9/96 – 9/97
Cooper Hospital University Medical Center
Camden, NJ
Department of Neurology
9/95 – 9/96
Clinical Neuropsychology Associates
Philadelphia, PA
9/94 – 8/99
Magee Rehabilitation Hospital
Brain Injury Rehabilitation Unit
Psychometrist
Philadelphia, PA
9/94 – 6/95
MEDICAL STAFF AFFILIATIONS:
Lee Memorial Hospital – The Rehabilitation Hospital
Brain Injury & Spinal Cord Unit
Ft. Myers, FL
Neuropsychologist
2000 – 2001
Memorial Hospital Pembroke
Memory Disorder Center
Pembroke Pines, FL
Neuropsychologist
2002 – Present
EXPERIENCE:
Sunrise Medical Group
Hollywood, FL
Neuropsychologist
2001 – Present
Sunrise Clinical Research, Inc
Hollywood, FL
Investigator
2002 – Present
Neurology Clinical Research, Inc.
Sunrise, FL
2009 – Present
TEACHING EXPERIENCE:
Mt. Sinai Medical Center
Miami Beach, FL
Neuropsychological Lectures
9/99 – 9/00
Philadelphia College of Osteopathic Medicine
Philadelphia, PA
Guest Lecturer- Neuroanatomy
4/97 – 6/97
Drexel University
Philadelphia, PA
Teaching Assistant
9/93 – 9/94
PROFESSIONAL AFFILIATIONS:
National Academy of Neuropsychology
PUBLICATIONS:
Book Chapter
Libon, D.J., Freeman, R.Q., Giovannetti, T., Lamar, M., Cloud, B.S., Stern, R.A., and Kaplan, E. (2002). The Rey-Osterrieth Complex Figure and Visuoconstructional Impairment in Cortical and Subcortical Dementia. In J. Knight & E. Kaplan (Eds), The Rey-Osterrieth Complex Figure: Clinical and Research Application. Odessa, FL: Psychological Assessment Resources.
Articles
Caregivers’ Judgments of the Functional
Abilities of the Alzheimer’s Disease Patient: A
Comparison of Proxy Reports and Objective
Measures of the Functional Status
Loewenstein, DA., Arguelles, S., Bravo, M.,
Freeman, RQ., Arguelles, T., Acevedo, A., &
Eisdorfer, C. Journal of Gerontology,56 (2), 78-84 (2001)
Visuoconstructional Problems in Dementia:
Contribution of Executive Systems Functions.
Freeman, RQ., Giovanetti, T., Lamar, M.,
Cloude, B., Stern, R., Kaplan E., & Libon
Neuropsychology, 14, 3.415-426(2000)
Abstracts
Characteristics of Digit Span in Alzheimer’s disease patients. L Schram, D Loewenstein, A Acevedo, R Freeman, and E Mendelson Arch Clin Neuropsychology, November 2000; 15: 746 – 747
Intrusion errors in learning and memory: a comparison of Alzheimer’s disease and vascular dementia
Arch Clin Neuropsychology, November 2000; 15: 748 – 749
RQ Freeman
PRESENTATIONS & LECTURES
Behavioral Modification & the Neurologically Impaired.
The Rehabilitation Hospital at Lee Memorial
Hospital
June/July 2001
Rehabilitation Psychology
The Rehabilitation Hospital at Lee Memorial
Hospital
February, April, July 2001
Freeman, RQ., Loewenstein, DA., Acevedo,
A., & Schram, L.
Intrusion Errors in Learning & Memory: A comparison of Alzheimer’s Disease and Vascular Dementia. Poster Presented at the National Academy of Neuropsychology, Orlando Florida (2000)
Neuropsychological Sequelea of Cardiac Disease.
University of Miami School of Medicine
Jackson Memorial Hospital-Neuropsychology
Rounds November 1999
Neurobehavioral Markers in Alzheimer’s Disease
University of Miami School of Medicine-Jackson Memorial Hospital – Neuropsychology
Rounds May 2000
RESEARCH EXPERIENCE:
(Rater/ Sub-Investigator)
A Phase II Double-Blind, Randomized, Dose Ranging, Placebo-Controlled, Multicenter, Safety and
Efficacy Evaluation of Three Doses of XX XXXX in Patients with Mild to Moderate Dementia of the
Alzheimer’s Type
A Fourteen-Week Placebo-Controlled Dose Response Efficacy and Safety Study of XXXXX in Early
Parkinson’s Disease Patient (Study for Proof of Concept in Early Parkinson’s Disease of a Triple
Reuptake Inhibitor, XX-XXX/SCEPTRE)
A dose-ranging, placebo-controlled study of XXXX.XXXX-XX at the dose of 0.5 mg, 2 mg
and 8 mg for 12 weeks in patients with mild to-moderate Alzheimer’s Disease
A Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and
Efficacy of XX-XXXX 25 mg in Slowing the Progression o Alzheimer’s Disease
A ONE YEAR, MULITCENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED EVALUATION OF THE EFFICACY AND SAFETY OF DONEPEZIL
HYDROCHLORIDE (XXXXX) IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2
STUDY TO EVALUATE THE SAFETY AND EFFICACY OF XXXXX IN SUBJECTS WITH MILD TO
MODERATE ALZHEIMER’S DISEASE
Phase 3 Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily
Treatment with XXX XXX on Measures of Cognitive and Global Function in Subjects with Mild to
Moderate Dementia of the Alzheimer’s Type
A randomized, multi-center, double-blind, placebo-controlled, 18-month study of the efficacy of
XXXXXXXXXX in patients with mild-to moderate dementia of the Alzheimer’s type
An Open-label Exploratory Study with Memantine of Selected Measures of Volumetric MRI and Cognition in Patients with Moderate Dementia of the Alzheimer’s Type
SAFETY, TOLERABILITY, AND EFFICACY STUDY OF ORAL KETASYN™ (XX-XXXX)
ADMINISTERED FOR NINETY DAYS IN SUBJECTS WITH PROBABLE ALZHEIMER’S DISEASE OF MILD TO MODERATE SERVERTIY
A MULTI-SITE, CROSS-SECTIONAL, NON TREATMENT, PROSPECTIVE TRIAL TO COLLECT BIO
FLUIDS AND NEUROPSYCHIATRIC DATA FROM COGNITIVELY NORMAL ELDERLY SUBJECTS
Open Label Study of the Effect of daily Treatment with XXX-XXXX in Subjects with Dementia of the
Alzheimer’s Type
Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect
Of Daily Treatment with XXX-XXX on Measures of Cognition, Activities of Daily Living and Global
Function in Subjects with Mild Dementia of the Alzheimer’s Type
A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study with a
20-week, Open-Label Extension Evaluating the Tolerability and Safety of Switching from Donepezil to an initial dose of 5cm² Rivastigmine Patch Formulation in Patients with Probable Alzheimer’s Disease.
A 28-Week Open Label Extension Study Evaluating the Safety and Tolerability of Donepezil
hydrochloride (XXX) in Subjects with Mild Cognitive Impairment
A Double-Blind, Randomized, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 8
Week Treatment of XXXXXXX X mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer’s
Disease Subjects
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral
XXXXXXX (XXX-XXX) in Alzheimer’s Disease
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Efficacy,
Safety and Tolerability of XXXXXXXXXX as an XXXXXXXXXX Fast Dissolving Tablet in the Treatment
Of Parkinson’s Disease Patients
Phase 3, parallel, placebo-controlled, dose/response, delayed-start 88 week study in patients with mild to moderate Alzheimer’s disease
A 76-week, prospective, open-label, multicenter study to evaluate the long-term effect of Exelon®
capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson’s disease (PDD)
SPECIAL INTERESTS:
Miami Dolphins Cheerleader
Miami Dolphins Ltd., Inc.
Davie, FL
2006 – 2007
Philadelphia Eagles Cheerleader
Philadelphia Eagles, LLC
Philadelphia, PA
1995 -1999
